Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 11, Pages 7933-7945Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c00472
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [22077015]
- Nanjing Biorn Life Science Co. Ltd
Ask authors/readers for more resources
In this study, a novel platinum(IV) prodrug was developed to inhibit cancer stem cells and overcome cisplatin resistance in non-small cell lung cancer, demonstrating potent antitumor activity.
Acquired resistance remains a major barrier for the treatment of non-small cell lung cancer, while cancer stem cells (CSCs) usually lead to the occurrence of drug resistance. We herein report a series of platinum(IV) prodrugs containing CSCs-inhibitory species derived from a known CSCs inhibitor BBI608 in the axial position. Among them, complex 15 exerted the most potent cytotoxicity against A549 and A549/CDDP cancer cells. Besides, 15 could suppress cancer cell stemness, superior to BBI608, and overcome cisplatin resistance. Following assays indicated that an enhanced intracellular accumulation of 15 effectively triggered DNA damage, induced ROS generation, activated mitochondrial apoptosis pathway, and suppressed cell motility via p53 pathway in A549/CDDP cells. In vivo tests indicated that 15 exhibited potent antitumor effects without causing loss in the body weight. Our study provides a novel and efficient approach to promote the antitumor activity of platinum-based prodrugs and overcome cisplatin resistance via inhibiting cancer cell stemness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available